Cohort Expansion Study of Neoadjvuant Immunoradiotherapy in Locoregionally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
International Journal of Radiation Oncology, Biology, Physics
We recently reported the results of a phase Ib clinical trial in which 10 patients with previously untreated stage I-III (AJCC 8 th Ed) p16+ head and neck squamous cell carcinoma (HNSCC) underwent neoadjuvant immunoradiotherapy (NIRT) with nivolumab 240mg IV q2 weeks x3 prior to surgery ( NCT03247712). Stereotactic body radiation (SBRT) to gross tumor volume was delivered between doses 1 & 2 of nivolumab in one of two dose finding cohorts: Cohort A (40Gy, 8Gy X5, M-F); and Cohort B (24Gy, 8Gy X3, M-W-F). The pathologic complete response rate (pCR) was 90% and all patients were successfully down-staged prior to surgery. Here we aim to test the hypothesis that nivolumab contributed to the exceptional local response to radiation by modulating the tumor microenvironment via blockade of upregulated PD-L1.
Earle A. Chiles Research Institute
Bell, Richard Bryan; Leidner, Rom; Young, Kristina H; Curti, Brendan; Couey, Marcus; Patel, Ashish; Watters, Amber L; Xiao, Hong D; Morris, George; Rushforth, Lessli; Gough, Michael J.; and Crittenden, Marka R, "Cohort Expansion Study of Neoadjvuant Immunoradiotherapy in Locoregionally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma" (2020). Articles, Abstracts, and Reports. 3942.